I. V. Reyes-Pérez

Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis: association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) and clinical activity

J. Muñóz-Valle, I. V. Reyes-Pérez, P. E. Sánchez-Hernández, 2019, Clinical Rheumatology.

Myositis-Specific Antibodies and Myositis-Associated Antibodies in Patients With Idiopathic Inflammatory Myopathies From the PANLAR Myositis Study Group

M. Fritzler, L. Andrade-Ortega, I. V. Reyes-Pérez, 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Impact of Pharmaceutical Education on Medication Adherence and Its Clinical Efficacy in Patients with Type 2 Diabetes and Systemic Arterial Hypertension

Sally Haack, I. V. Reyes-Pérez, O. Graciano-Machuca, 2022, Patient preference and adherence.

Targeting inflammasome-dependent mechanisms as an emerging pharmacological approach for osteoarthritis therapy

I. V. Reyes-Pérez, P. Bhattaram, Luis Alexis Hernández-Palma, 2022, iScience.

Targeting MyD88 Downregulates Inflammatory Mediators and Pathogenic Processes in PBMC From DMARDs-Naïve Rheumatoid Arthritis Patients

I. V. Reyes-Pérez, P. Bhattaram, E. Oregon-Romero, 2021, Frontiers in Pharmacology.

PTPN22 +788 G>A (R263Q) Polymorphism is Associated with mRNA Expression but it is not a Susceptibility Marker for Rheumatoid Arthritis Patients from Western Mexico

J. Muñóz-Valle, I. V. Reyes-Pérez, G. Martínez-Bonilla, 2019, Biochemical Genetics.